|
 |
|
|||||||
|
|||||||||
© American Diabetes Association ®, Inc., 2006
Feature Article |
Screening for Coronary Disease in Diabetes: When and How
 |
Abstract |
|---|
 Top Abstract IntroductionIf Diabetes Is a...Screening for Silent IschemiaScreening for Subclinical...RecommendationsSummaryREFERENCES |
|---|
IN BRIEF
Coronary atherosclerosis and silent ischemia are highly prevalent in patients with diabetes. Identification of subclinical atherosclerosis and ischemia in asymptomatic patients with diabetes is valuable for risk stratification and for guiding therapy. This article reviews methods of screening and proposes how to implement them in practice.
|
Introduction |
|---|
|
TopAbstractIntroductionIf Diabetes Is a...Screening for Silent IschemiaScreening for Subclinical...RecommendationsSummaryREFERENCES |
|---|
Cardiovascular disease is the leading cause of death in patients with diabetes, accounting for as many as 80% of deaths in these patients.1 The risk of myocardial infarction (MI) in patients with diabetes is similar to that of patients without diabetes who have had a previous MI.2 Autopsy studies have identified a high prevalence of coronary atherosclerosis in patients with diabetes, even among those without clinical coronary heart disease (CHD). Goraya et al.3 found advanced coronary lesions in nearly three-fourths of individuals with diabetes who did not have clinically apparent CHD; > 50% of asymptomatic individuals had multivessel disease. The prevalence of coronary calcification is similar in asymptomatic individuals with type 2 diabetes and individuals without diabetes who have symptomatic CHD.4 Hence, diabetes is considered to be a "CHD equivalent."5 Furthermore, the prevalence of silent ischemia among asymptomatic individuals with diabetes is high, ranging from 20 to > 50% of patients.6,7 The question thus arises as to whether asymptomatic patients with diabetes should be screened for CHD and, if so, when and by which modality.
|
If Diabetes Is a CHD Equivalent, Why Screen? |
|---|
|
TopAbstractIntroductionIf Diabetes Is a...Screening for Silent IschemiaScreening for Subclinical...RecommendationsSummaryREFERENCES |
|---|
If we approach all patients with diabetes as if they have already been diagnosed with CHD, what is the rationale for trying to detect the presence of CHD? The reason is that there are important prognostic, management, and therapeutic implications from identifying CHD in patients with diabetes. Patients with diabetes and CHD carry a significantly worse prognosis than those a with diabetes who do not have CHD.2 In addition to risk stratification, detecting CHD may improve patient motivation to adhere to medical therapy.8 From a management perspective, patients with highrisk characteristics on testing for ischemia may belong to a subset that would benefit from coronary angiography and revascularization. With regard to medical therapy, the knowledge that a patient with diabetes has CHD may indicate the need to initiate or intensify pharmacological therapy with ß-blockers (if ischemia is present), statins, or ACE inhibitors. Current National Cholesterol Education Program guidelines recommend an LDL cholesterol goal of < 100 mg/dl for patients with diabetes without CHD; if CHD is present, the LDL goal is < 70 mg/dl.9 Not all patients with diabetes are considered candidates for ACE inhibitor therapy; those with CHD should be treated with these agents.10 Hence, detecting CHD with or without ischemia helps refine the management of asymptomatic patients with diabetes.
|
Screening for Silent Ischemia |
|---|
|
TopAbstractIntroductionIf Diabetes Is a...Screening for Silent IschemiaScreening for Subclinical...RecommendationsSummaryREFERENCES |
|---|
Existing guidelines for screening
Guidelines from the American College of Cardiology/American Heart Association (ACC/AHA) and the American Diabetes Association (ADA) recommend graded exercise testing in asymptomatic patients with diabetes who plan to begin a moderate- to highintensity exercise program and are at increased risk for CHD based on one or more of the following factors: age > 35 years, age > 25 years and type 2 diabetes of > 10 years' duration or type 1 diabetes of > 15 years' duration, any additional risk factors for CHD, and the existence of microvascular disease, such as proliferative retinopathy or nephropathy (including microalbuminuria), autonomic neuropathy, or peripheral vascular disease.11,12 The greater the number of risk factors, the higher the pretest probability, thus increasing the likelihood that screening will result in useful prognostic information.
The diagnostic accuracy of stress testing is improved when combined with imaging. The ACC Foundation and American Society of Nuclear Cardiology have deemed it appropriate to perform single-photon emission computed tomography (SPECT) myocardial perfusion imaging for asymptomatic individuals with diabetes.13 It is also considered appropriate to repeat a SPECT study in patients with diabetes at least 2 years after a previously normal SPECT study.
Exercise treadmill testing
In a retrospective study of 1,282 male patients without prior MI who
underwent exercise stress tests after presenting with chest pain, Lee et
al.14 found the
sensitivity of exercise treadmill testing to be 47% in patients with diabetes,
with a specificity of 81%. The positive predictive value in individuals with
diabetes was 85%; the negative predictive value was 41%. For those who did not
have diabetes, the sensitivity of exercise testing was 52%, specificity 80%,
positive predictive value 78%, and negative predictive value 55%,
demonstrating similar diagnostic and prognostic characteristics in patients
with and without diabetes.
In another study of asymptomatic, higher-risk patients with diabetes, Bacci et al.15 found the positive predictive accuracy of the exercise treadmill test to be 79%. Those with false-negative tests tended to have a longer duration of diabetes and a higher prevalence of peripheral vascular disease.
Nuclear stress imaging
Nuclear stress imaging, the most widely studied stress testing modality in
patients with diabetes, has a sensitivity of 88% and specificity of 74% in the
population at large, with similar diagnostic characteristics among individuals
with
diabetes.16,17
In the Detection of Ischemia in Asymptomatic Diabetics study, Wackers et
al.6 used adenosine
SPECT imaging to screen 1,123 asymptomatic patients with type 2 diabetes for
myocardial ischemia. The average age was 61 years, with an average duration of
diabetes of 8 years. Twenty-two percent of these patients were found to have
silent ischemia, and 41% of the abnormal tests would not have been predicted
based on the 1998 ADA screening guidelines alone. Notably, the presence of
cardiac autonomic dysfunction was strongly associated with silent ischemia in
this study.
Rajagopalan et
al.18 examined the
relationship of ischemia by SPECT with angiographic findings and total
mortality in 1,427 asymptomatic patients with diabetes who did not have known
CHD. The average age of subjects was 60 years, and the median duration of
diabetes was 10 years. Eighteen percent had high-risk stress SPECT results,
defined as a summed stress score 
47 points. Sixty-one percent of patients
with highrisk results had angiographically highrisk coronary artery disease
(CAD). Subjects with high-risk findings had a high annual mortality rate of
5.9%. Of note, those with low-risk scans also had a relatively high annual
mortality rate of 3.6%. The presence of Q waves on electrocardiogram and the
diagnosis of peripheral arterial disease were the strongest predictors of
abnormal stress test results.
De Lorenzo et al.19 also evaluated the utility of SPECT imaging in screening asymptomatic subjects with diabetes. One hundred and eighty asymptomatic patients with diabetes underwent 2-day stress SPECT testing and were followed for 36 ± 18 months. Twenty-six percent of patients had perfusion defects, and clinical variables were not associated with the type of defect or subsequent events. "Hard" events were defined as MI or death due to a cardiac cause; "total" events included MI, cardiac death, or revascularization. Two percent of hard events and 5% of total events per year occurred in patients who had a normal SPECT. By comparison, these numbers increased to 9% of hard events and 38% of total events in those with an abnormal SPECT. Thus, the presence of an abnormal SPECT test in these asymptomatic patients seemed to provide added prognostic value over clinical predictors alone.
In a multicenter cohort consisting of 370 asymptomatic patients with diabetes who also had at least two additional cardiac risk factors, Valensi et al.20 identified silent ischemia in 35% of patients using stress SPECT imaging as well as electrocardiographic stress testing. These patients were followed for 38 ± 23 months, with a significant association found between positive stress results and subsequent cardiac events. The prevalence of silent ischemia was 43% among patients > 60 years of age versus 30% in patients < 60 years of age. Interestingly, the association between the presence of silent ischemia and subsequent cardiac events was statistically significant in the patients > 60 years old but not in those < 60 years old.
Stress echocardiography
Data specifically addressing the predictive value of stress
echocardiography in patients with diabetes, particularly those who are
asymptomatic, are limited. In a study by Hennessy et
al.,21 52 patients
with diabetes were evaluated by dobutamine stress echocardiography, with a
sensitivity for CHD detection of 82% and a specificity of 54%. The positive
predictive value of dobutamine stress echocardiography was 84%, and the
negative predictive value was 50%.
Elhendy et al.22 followed 563 patients with diabetes who also had known or suspected CAD and had undergone exercise stress echocardiography over a median follow-up period of 3 years. Event rates were not well predicted by prior angina or stress-induced angina. Patients with multiple wall motion abnormalities had the highest event rates, and echocardiographic abnormalities in a multivessel distribution during exercise provided prognostic information beyond that afforded by clinical and exercise data alone. Conversely, patients with a normal exercise echocardiogram had no events at 2 years. The event rate increased to 7.6% at 5 years, suggesting that, as with nuclear stress testing, the frequency of such stress testing should be in the range of every 2-3 years for the reassessment of risk in patients with diabetes.
|
Screening for Subclinical Atherosclerosis |
|---|
|
TopAbstractIntroductionIf Diabetes Is a...Screening for Silent IschemiaScreening for Subclinical...RecommendationsSummaryREFERENCES |
|---|
Most MIs originate from atherosclerotic plaque that is not obstructive and therefore would not be detected by a test for myocardial ischemia.23 In addition, patients with diabetes and a normal SPECT have a higher event rate than patients without diabetes who have a normal SPECT.24 These facts provide the rationale to search noninvasively for the presence of subclinical atherosclerosis. The two imaging modalities most commonly evaluated for this purpose are coronary artery calcium (CAC) scanning and measurement of carotid intimamedia thickness (cIMT).
CAC
A number of studies have revealed a higher prevalence of CAC in patients
with diabetes. Schurgin et
al.25 scanned 139
patients with diabetes for CAC and compared their findings with individuals
who did not have diabetes. Seventy-five percent had a CAC score > 0,
indicating the presence of subclinical atherosclerosis. Twenty-five percent
had CAC scores 
400, compared with 7.2% of randomly selected and 14.4% of
matched control subjects without diabetes. The average age of subjects in the
group with diabetes was 58 years. Wolfe et
al.26 conducted a
retrospective analysis of CAC data for 71 asymptomatic subjects with type 2
diabetes compared with 1,481 asymptomatic patients without diabetes and 71
randomly selected matched patients without diabetes. CAC scores were higher in
patients with type 2 diabetes than in those without, independent of
traditional cardiac risk factors. The odds ratio for the presence of any
coronary calcification (CAC score > 0) was 2.9 in patients with type 2
diabetes. The average age of the patients with diabetes in this study was 55
years. In the Prospective Evaluation Identification of Decompensation by IGT
Test study, Elkeles et
al.27 performed CAC
screening in 495 subjects with type 2 diabetes, none of whom had a history of
CHD. The mean age of these subjects was 62.9 years, with a median duration of
diabetes of 8 years. The median CAC score was 119, and duration of diabetes
was significantly associated with increased CAC score.
In a study by Raggi et
al.,28 10,377
asymptomatic patients (903 of whom had type 2 diabetes) were followed for a
mean of 5 years after undergoing CAC screening. The primary end point of the
study was all-cause mortality. On average, patients with diabetes had a higher
CAC score than patients without diabetes, and for every increase in CAC score,
there was a greater increase in mortality for subjects with diabetes than for
those without. Notably, patients both with and without diabetes who were found
to have no coronary calcification had a low risk of death (
1% at 5
years).
cIMT
cIMT is a significant predictor of coronary
events.29-31
In the Insulin Resistance Atherosclerosis
Study,32 diabetes
was associated with increased common cIMT. The mean duration of diabetes was 7
years. In the Atherosclerosis Risk in Communities
study,33 a cohort
study of 15,792 asymptomatic adults aged 45-64 years, adjusted mean wall
thickness was thicker in subjects with diabetes than in those without.
Patients with newly detected type 2 diabetes were shown to have increased cIMT
in a case-controlled study by Temelkova-Kurktschiev et
al.34 Seventy-one
patients with newly diagnosed type 2 diabetes with a mean age of 57 years had
significantly increased common cIMT compared with control subjects.
Few prospective studies exist using cIMT measurements to predict cardiac events in patients with diabetes. Yamasaki et al.35 followed 287 patients with type 2 diabetes for 3 years and determined that baseline cIMT independently predicted nonfatal CHD events.
|
Recommendations |
|---|
|
TopAbstractIntroductionIf Diabetes Is a...Screening for Silent IschemiaScreening for Subclinical...RecommendationsSummaryREFERENCES |
|---|
Identification of subclinical atherosclerosis and ischemia in asymptomatic patients with diabetes is worthwhile for risk stratification and for guiding therapy. Current guidelines fail to identify an unacceptably large proportion of patients, yet evidence is not currently sufficient to define the optimal screening strategy for asymptomatic patients with diabetes in terms of clinical and cost-effectiveness outcomes. In the absence of such evidence, we propose an approach, based on our synthesis of the current evidence, to identify more highrisk individuals in a presymptomatic phase (Figure 1). We acknowledge that further research is needed to define the optimal approach.
|
Initiate ß-blocker and ACE
inhibitor; intensify statin-based therapy to achieve LDL cholesterol < 70
mg/dl. 
The benefit of revascularization in a patient with no symptoms
and no high-risk features is unestablished.
We recommend that patients with type 1 or type 2 diabetes who are 60
years of age or who have had diabetes for 15 years undergo a stress
imaging test for myocardial ischemia. Those with findings consistent with
severe ischemia should be referred for cardiac catheterization. In addition,
those patients should be started on ß-blocker and ACE inhibitor therapy,
and statin-based lipid lowering should be intensified to achieve an LDL
cholesterol of < 70 mg/dl ("tailored medical therapy"). Those
with ischemia that is not severe should not necessarily be referred for
cardiac catheterization because the benefit of revascularization in such
patients has not been demonstrated. These patients should have tailored
medical therapy as described above. Patients without ischemia may be
considered for screening for subclinical atherosclerosis. Alternatively,
because the likelihood of subclinical atherosclerosis is 60-70% in such
patients,4,28
its presence could be presumed and appropriate medical therapy implemented.
Asymptomatic patients with diabetes who are < 60 years of age and who have
had diabetes for > 7 years but < 15 years should undergo screening for
subclinical atherosclerosis with CAC scoring or carotid ultrasonography. Those
with moderate to severe atherosclerosis should be treated with appropriate
medical therapy and referred for stress imaging. Those with minimal
atherosclerosis should have tailored medical therapy only.
|
Summary |
|---|
|
TopAbstractIntroductionIf Diabetes Is a...Screening for Silent IschemiaScreening for Subclinical...RecommendationsSummaryREFERENCES |
|---|
Subclinical atherosclerosis and silent ischemia in asymptomatic patients with diabetes is common. Screening patients according to traditional risk factors and current guidelines alone will frequently fail to identify CHD, thus losing the opportunity for early diagnosis and intensified management. A more aggressive approach to identifying asymptomatic coronary disease should therefore be considered in this patient population.
|
Footnotes |
|---|
Yasmine S. Ali, MD, is a fellow in cardiovascular medicine, and David J. Maron, MD, is an associate professor of medicine in the Division of Cardiovascular Medicine at Vanderbilt University Medical Center in Nashville, Tenn.
Note of disclosure: Dr. Maron is an employee of and stockholder in Cardiovascular Services of America, which provides outpatient cardiac catheterization and computed tomography angiography services.
|
REFERENCES |
|---|
|
TopAbstractIntroductionIf Diabetes Is a...Screening for Silent IschemiaScreening for Subclinical...RecommendationsSummaryREFERENCES |
|---|
1 Bonow RO, Bohannon N, Hazzard W: Risk stratification in coronary artery disease and special populations. Am J Med101 : 17S-22S,1996 [discussionAm J Med 101:22S -24S, 1996][Medline]
2 Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality
from coronary heart disease in subjects with type 2 diabetes and in
nondiabetic subjects with and without prior myocardial infarction.
N Engl J Med 339:229
-234, 1998
3 Goraya TY, Leibson CL, Palumbo PJ, Weston SA, Killian JM, Pfeifer
EA, Jacobsen SJ, Frye RL, Roger VL: Coronary atherosclerosis in diabetes
mellitus: a population-based autopsy study. J Am Coll
Cardiol 40:946
-953, 2002
4 Khaleeli E, Peters SR, Bobrowsky K, Oudiz RJ, Ko JY, Budoff MJ: Diabetes and the associated incidence of subclinical atherosclerosis and coronary artery disease: implications for management. Am Heart J 141: 637-644,2001[Medline]
5 Executive Summary of the Third Report of the National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment
of High Blood Cholesterol in Adults (Adult Treatment Panel III).
JAMA 285:2486
-2497, 2001
6 Wackers FJ, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ,
Taillefer R, Wittlin SD, Heller GV, Filipchuk N, Engel S, Ratner RE,
Iskandrian AE: Detection of silent myocardial ischemia in asymptomatic
diabetic subjects: the DIAD study. Diabetes Care27
: 1954-1961,2004
7 Di Carli MF, Hachamovitch R: Should we screen for occult coronary
artery disease among asymptomatic patients with diabetes? J Am Coll
Cardiol 45:50
-53, 2005
8 Kalia NK, Miller LG, Nasir K, Blumenthal RS, Agrawal N, Budoff MJ: Visualizing coronary calcium is associated with improvements in adherence to statin therapy. Atherosclerosis185 : 394-399,2006[Medline]
9 Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake
DB, Pasternak RC, Smith SC Jr, Stone NJ: Implications of recent clinical
trials for the National Cholesterol Education Program Adult Treatment Panel
III guidelines. Circulation110
: 227-239,2004
10 Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC,
Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T,
Pfeffer MA, Taubert KA: AHA/ACC guidelines for secondary prevention for
patients with coronary and other atherosclerotic vascular disease: 2006
update: endorsed by the National Heart, Lung, and Blood Institute.
Circulation 113:2363
-2372, 2006
11 Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF,
Froelicher VF, Mark DB, McCallister BD, Mooss AN, O'Reilly MG, Winters WL Jr,
Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka
LF, Jacobs AK, Russell RO, Smith SC Jr: ACC/AHA 2002 guideline update for
exercise testing: summary article: a report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines
(Committee to Update the 1997 Exercise Testing Guidelines).
Circulation 106:1883
-1892, 2002
12 Zinman B, Ruderman N, Campaigne BN, Devlin JT, Schneider SH: Physical activity/exercise and diabetes. Diabetes Care27 (Suppl. 1):S58 -S62, 2004
13 Brindis RG, Douglas PS, Hendel RC, Peterson ED, Wolk MJ, Allen JM,
Patel MR, Raskin IE, Hendel RC, Bateman TM, Cerqueira MD, Gibbons RJ, Gillam
LD, Gillespie JA, Hendel RC, Iskandrian AE, Jerome SD, Krumholz HM, Messer JV,
Spertus JA, Stowers SA: ACCF/ASNC appropriateness criteria for single-photon
emission computed tomography myocardial perfusion imaging (SPECT MPI): a
report of the American College of Cardiology Foundation Quality Strategic
Directions Committee Appropriateness Criteria Working Group and the American
Society of Nuclear Cardiology endorsed by the American Heart Association.
J Am Coll Cardiol 46:1587
-1605, 2005
14 Lee DP, Fearon WF, Froelicher VF: Clinical utility of the exercise
ECG in patients with diabetes and chest pain. Chest119
: 1576-1581,2001
15 Bacci S, Villella M, Villella A, Langialonga T, Grilli M, Rauseo A, Mastroianno S, De Cosmo S, Fanelli R, Trischitta V: Screening for silent myocardial ischaemia in type 2 diabetic patients with additional atherogenic risk factors: applicability and accuracy of the exercise stress test. Eur J Endocrinol 147:649 -654, 2002[Abstract]
16 Albers AR, Krichavsky MZ, Balady GJ: Stress testing in patients
with diabetes mellitus: diagnostic and prognostic value.
Circulation 113:583
-592, 2006
17 Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS,
O'Gara PT, Carabello BA, Russell RO Jr, Cerqueira MD, St John Sutton MG,
DeMaria AN, Udelson JE, Kennedy JW, Verani MS, Williams KA, Antman EM, Smith
SC Jr, Alpert JS, Gregoratos G, Anderson JL, Hiratzka LF, Faxon DP, Hunt SA,
Fuster V, Jacobs AK, Gibbons RJ, Russell RO: ACC/AHA/ASNC guidelines for the
clinical use of cardiac radionuclide imaging—executive summary: a report
of the American College of Cardiology/American Heart Association Task Force on
Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for
the Clinical Use of Cardiac Radionuclide Imaging).
Circulation 108:1404
-1418, 2003
18 Rajagopalan N, Miller TD, Hodge DO, Frye RL, Gibbons RJ:
Identifying high-risk asymptomatic diabetic patients who are candidates for
screening stress single-photon emission computed tomography imaging.
J Am Coll Cardiol 45:43
-49, 2005
19 De Lorenzo A, Lima RS, Siqueira-Filho AG, Pantoja MR: Prevalence and prognostic value of perfusion defects detected by stress technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography in asymptomatic patients with diabetes mellitus and no known coronary artery disease. Am J Cardiol 90:827 -832, 2002[Medline]
20 Valensi P, Paries J, Brulport-Cerisier V, Torremocha F, Sachs RN,
Vanzetto G, Cosson E, Lormeau B, Attali JR, Marechaud R, Estour B, Halimi S:
Predictive value of silent myocardial ischemia for cardiac events in diabetic
patients: influence of age in a French multicenter study. Diabetes
Care 28:2722
-2727, 2005
21 Hennessy TG, Codd MB, Kane G, McCarthy C, McCann HA, Sugrue DD: Evaluation of patients with diabetes mellitus for coronary artery disease using dobutamine stress echocardiography. Coron Artery Dis 8: 171-174,1997[Medline]
22 Elhendy A, Arruda AM, Mahoney DW, Pellikka PA: Prognostic
stratification of diabetic patients by exercise echocardiography. J
Am Coll Cardiol 37:1551
-1557, 2001
23 Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M, Borrico S, Gorlin R, Fuster V: Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 12:56 -62, 1988[Abstract]
24 Giri S, Shaw LJ, Murthy DR, Travin MI, Miller DD, Hachamovitch R,
Borges-Neto S, Berman DS, Waters DD, Heller GV: Impact of diabetes on the risk
stratification using stress single-photon emission computed tomography
myocardial perfusion imaging in patients with symptoms suggestive of coronary
artery disease. Circulation105
: 32-40,2002
25 Schurgin S, Rich S, Mazzone T: Increased prevalence of significant
coronary artery calcification in patients with diabetes. Diabetes
Care 24: 335-338,2001
26 Wolfe ML, Iqbal N, Gefter W, Mohler ER 3rd, Rader DJ, Reilly MP: Coronary artery calcification at electron beam computed tomography is increased in asymptomatic type 2 diabetics independent of traditional risk factors. J Cardiovasc Risk 9:369 -376, 2002[Medline]
27 Elkeles RS, Feher MD, Flather MD, Godsland IF, Nugara F, Richmond W, Rubens MB, Wang D: The association of coronary calcium score and conventional cardiovascular risk factors in type 2 diabetic subjects asymptomatic for coronary heart disease (the PREDICT Study). Diabet Med 21:1129 -1134, 2004[Medline]
28 Raggi P, Shaw LJ, Berman DS, Callister TQ: Prognostic value of
coronary artery calcium screening in subjects with and without diabetes.
J Am Coll Cardiol 43:1663
-1669, 2004
29 Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR,
Clegg LX: Association of coronary heart disease incidence with carotid
arterial wall thickness and major risk factors: the Atherosclerosis Risk in
Communities (ARIC) Study, 1987-1993. Am J Epidemiol146
: 483-494,1997
30 Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, Azen SP:
The role of carotid arterial intima-media thickness in predicting clinical
coronary events. Ann Intern Med128
: 262-269,1998
31 Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE: Common
carotid intima-media thickness and risk of stroke and myocardial infarction:
the Rotterdam Study. Circulation96
: 1432-1437,1997
32 Wagenknecht LE, D'Agostino R Jr, Savage PJ, O'Leary DH, Saad MF,
Haffner SM: Duration of diabetes and carotid wall thickness. The Insulin
Resistance Atherosclerosis Study (IRAS). Stroke28
: 999-1005,1997
33 Folsom AR, Eckfeldt JH, Weitzman S, Ma J, Chambless LE, Barnes RW, Cram KB, Hutchinson RG: Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke 25:66 -73, 1994[Abstract]
34 Temelkova-Kurktschiev TS, Koehler C, Leonhardt W, Schaper F, Henkel
E, Siegert G, Hanefeld M: Increased intimal-medial thickness in newly detected
type 2 diabetes: risk factors. Diabetes Care22
: 333-338,1999
35 Yamasaki Y, Kodama M, Nishizawa H, Sakamoto K, Matsuhisa M,
Kajimoto Y, Kosugi K, Shimizu Y, Kawamori R, Hori M: Carotid intima-media
thickness in Japanese type 2 diabetic subjects: predictors of progression and
relationship with incident coronary heart disease. Diabetes
Care 23:1310
-1315, 2000
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Roelker Screening for Coronary Artery Disease in Patients With Diabetes Diabetes Spectr, July 1, 2008; 21(3): 166 - 171. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |